ArticleMolecular medicine (Cambridge, Mass.)2020
miRNA-23b as a biomarker of culture-positive neonatal sepsis.
Article in Molecular medicine (Cambridge, Mass.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- MicroRNA-23b: Roles, functions and mechanisms in tumor.Genes & diseases · 2026Review
- MicroRNA Profiling as a Novel Tool in the Diagnostics of Late-Onset Neonatal Sepsis: A Scoping Review.Children (Basel, Switzerland) · 2025Review
- Sensitivity of miRNA-181a, miRNA-23b and miRNA-16 in the Late-Onset Neonatal Sepsis: A Diagnostic Study.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2024Article
- Application of Advanced Molecular Methods to Study Early-Onset Neonatal Sepsis.International journal of molecular sciences · 2024Review
- MicroRNA Regulation in Infectious Diseases and Its Potential as a Biosensor in Future Aquaculture Industry: A Review.Molecules (Basel, Switzerland) · 2023Review
- The Endothelial Glycocalyx and Neonatal Sepsis.International journal of molecular sciences · 2022Review
- Role of miRNA dysregulation in sepsis.Molecular medicine (Cambridge, Mass.) · 2022Review
- MicroRNAs as Potential Diagnostic New Biomarkers in Diagnosis of Sepsis in Pediatric Patients.Reports of biochemistry & molecular biology · 2022Article
- Impact of Inherited Genetic Variants on Critically Ill Septic Children.Pathogens (Basel, Switzerland) · 2022Review
- AntiVIRmiR: A repository of host antiviral miRNAs and their expression along with experimentally validated viral miRNAs and their targets.Frontiers in genetics · 2022Article
- Diagnosis of neonatal sepsis: the past, present and future.Pediatric research · 2022Review
- Article
- Modes of action and diagnostic value of miRNAs in sepsis.Frontiers in immunology · 2022Review
- Correlation of serum miR-127 level with severity and prognosis of sepsis.American journal of translational research · 2022Article
- Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research.Pediatric research · 2022Review
- miRNomic Signature in Very Low Birth-Weight Neonates Discriminates Late-Onset Gram-Positive Sepsis from Controls.Diagnostics (Basel, Switzerland) · 2021Article
- Downregulation of miR-1184 serves as a diagnostic biomarker in neonatal sepsis and regulates LPS-induced inflammatory response by inhibiting IL-16 in monocytes.Experimental and therapeutic medicine · 2021Article
- miR-141 is negatively correlated with TLR4 in neonatal sepsis and regulates LPS-induced inflammatory responses in monocytes.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Stratified Management for Bacterial Infections in Late Preterm and Term Neonates: Current Strategies and Future Opportunities Toward Precision Medicine.Frontiers in pediatrics · 2021Review
- Correction to: miRNA-23b as a biomarker of culture-positive neonatal sepsis.Molecular medicine (Cambridge, Mass.) · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal sepsis remains an important cause of morbidity and mortality. The ability to quickly and accurately diagnose neonatal sepsis based on clinical assessments and laboratory blood tests remains difficult, where haemoculture is the gold standard for detecting bacterial sepsis in blood culture. It is also very difficult to study because neonatal samples are lacking.
methodsForty-eight newborns suspected of sepsis admitted to the Neonatology Department of the Mother-Child Specialized Hospital of Tlemcen. From each newborn, a minimum of 1-2 ml of blood was drawn by standard sterile procedures for blood culture. The miRNA-23b level in haemoculture was evaluated by RT-qPCR.
resultsmiR-23b levels increased in premature and full-term newborns in early onset sepsis (p < 0.001 and p < 0.005 respectively), but lowered in late onset sepsis in full-term neonates (p < 0.05) compared to the respective negative controls. miR-23b levels also increased in late sepsis in the negative versus early sepsis negative controls (p < 0.05). miR-23b levels significantly lowered in the newborns who died from both sepsis types (p < 0.0001 and p < 0.05 respectively). In early sepsis, miR-23b and death strongly and negatively correlated (correlation coefficient = - 0.96, p = 0.0019). In late sepsis, miRNA-23b and number of survivors (correlation coefficient = 0.70, p = 0.506) positively correlated.
conclusionsLowering miR-23b levels is an important factor that favours sepsis development, which would confirm their vital protective role, and strongly suggest that they act as a good marker in molecular diagnosis and patient monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.